A 12‐week, randomized, double‐blind, placebo‐controlled, four‐arm dose‐finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes
2019 ◽
Vol 22
(4)
◽
pp. 566-573
◽
Keyword(s):
Phase 2
◽